9. The Landmark Clinical Trial: Who Participated?

The phase 2 clinical trial for lepodisiran included 320 adults from ten countries, such as the US, China, and Germany, ensuring a broad and diverse participant group. All enrolled individuals had extremely high Lp(a) levels—on average, three times above the normal upper limit. This international approach strengthens the study’s relevance and impact.
For full study details, visit The New England Journal of Medicine.